Recent data link the incidence of intestinal GvHD (iGvHD) after allogeneic haematopoietic stem cell transplantation (aSCT) to exposure with piperacillin-tazobactam or imipenem-cilastatin. To assess relevance of timing, duration, sequence and combination of antibiotic treatment in this setting, we applied a time-dependent model to our aSCT cohort. Patients from the prospective Cologne Cohort of Neutropenic Patients (CoCoNut) undergoing aSCT from January 2007 to April 2013 were included into a time-dependent multivariate Cox proportional hazards regression model with backward-stepwise selection. In 399 eligible patients, cumulative antibiotic exposure (hazard ratio (HR) 2.46; 95% confidence interval (95% CI) 1.59-3.81; Po0.001) and exposure to sequential treatment with penicillin derivatives and carbapenems (HR 6.22, 95% CI 1.27-30.31), but not to the individual classes, were associated with iGvHD at day 100. Glycopeptides were assessed as a risk factor (HR 3.73, 95% CI 1.51-9.19), but not considered independent, since their use was dependent on previous exposure to penicillin derivatives and carbapenems. Patients with iGvHD presented with increased non-relapse mortality at day 365 (HR 3.51; 95% CI 2.10-5.89; Po0.001). We identified sequential exposure to penicillin derivatives and carbapenems as well as overall exposure to antibiotics as independent risk factors for iGVHD. Confirmation of these findings in larger, prospective cohorts is necessary.
INTRODUCTION
The prognosis of patients undergoing allogeneic haematopoietic stem cell transplantation (aSCT), used primarily for the treatment of haematologic malignancies, can be adversely affected by subsequent infections and GVHD. After conditioning chemotherapy, translocation of colonic commensal bacteria into the bloodstream is the most frequent source of bloodstream infection; 1 the gut mucosa is also a frequent target of GvHD. 2 Due to prolonged neutropenia after conditioning chemotherapy and subsequent immunosuppression, antibiotic treatment is usually inevitable in cases of fever. Potential associations of subsequent intestinal dysbiosis on the frequency and severity of downstream complications, in particular intestinal GVHD (iGvHD), have turned into a matter of concern.
Recently, Shono et al. 3 showed that the incidence of iGvHD was increased in patients treated with piperacillin-tazobactam or imipenem-cilastatin. Risk factor analysis revealed that antibiotic treatment with either aztreonam or cefepime versus piperacillintazobactam or imipenem-cilastatin was significantly associated with a decreased risk of GVHD-related mortality. Notably, piperacillin-tazobactam and imipenem-cilastatin are both highly active against obligate anaerobic bacteria, whereas cefepime and aztreonam have reduced activity against anaerobes. 3 Likewise, Weber et al. 4 reported that the use of rifaximin compared with ciprofloxacin/metronidazole lead to a lower treatment related mortality and higher overall survival within the first 12 months after aSCT.
While these studies were crucial in identifying the link between gut microbiota composition, iGVHD and non-relapse mortality (NRM), the specific relevance of timing, duration, sequence and combination of antibiotic treatment in this setting remains to be explored in depth. With this aim, we applied a time-dependent statistical model to our aSCT cohort.
PATIENTS AND METHODS Setting
For this study, data were retrieved from the prospective Cologne Cohort of Neutropenic Patients (CoCoNut; NCT01821456). The CoCoNut has been approved by the local institutional review board and ethics committee (ID 13-108). Data were analysed and reported in agreement with STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. 5 Data capture included age, sex, haematologic malignancies, type of conditioning regime, radiation, donor type, CMV status, immunosuppressants and antibiotic administered, beginning and end of neutropenia and dates of admission and discharge from the hospital.
In addition, haematopoietic cell transplantation-specific comorbidity index (HCT-CI) score, 6 incidence, maximum severity and type of GvHD, as well as post-transplant survival and potential cause of death were retrieved from the patient files. In order to facilitate the analysis, the HCT-CI score, with a theoretically possible range of 0-26, was collapsed into three groups (0, 1-3 and 43). The CoCoNut was searched for all patients undergoing aSCT between January 2007 and April 2013.
During the study period, all patients received fluoroquinolone prophylaxis starting with initiation of the conditioning regimen, unless the administration of fluoroquinolones was contraindicated. Patients not Aplastic anaemia (n = 12), biphenotypic leukaemia (n = 1), idiopathic thrombocytopenia (n = 1), osteomyelofibrosis (n = 5) and refractory anaemia (n = 2). Abbreviations: ATG = antithymocyte globulin; HCT-CI = haematopoietic cell transplantation-specific comorbidity index; MisMD = mismatched donor; MRD = matched related donor; MUD = matched unrelated donor; MMF = mycofenolate mofetil.
a Aplastic anaemia (n = 12), biphenotypic leukaemia (n = 1), idiopathic thrombocytopenia (n = 1), osteomyelofibrosis (n = 5) and refractory anaemia (n = 2).
b For patients without intestinal GvHD, the cumulative antibiotic exposure before the median time to diagnosis of intestinal GvHD (27.5 days) was used as a cutoff.
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Definitions and end points
Acute iGvHD was diagnosed by histology obtained during endoscopy (sigmoidoscopy or colonoscopy). If there was no pathology report available, diagnosis was exclusively based on macroscopic endoscopic evaluation. NRM was defined as any cause of death except death due to relapse or recurrence of the underlying malignancy. Neutropenia was defined as an absolute neutrophil count of less than 500 neutrophils/μL or, if not available, a white blood cell count less than 1000 leukocytes/μL. The cumulative antibiotic exposure was measured in days of therapy, whereas multiple antibiotics given on the same day were counted as multiple antibiotic days. 7 The cumulative antibiotic exposure was split into two groups (high and low exposure) using the R package cutoff finder. 8 
Statistical analysis
Statistical analyses were carried out using R for Statistical Computing (version 3.2.5, R Foundation for Statistical Computing, Vienna, Austria). 9 Continuous variables were presented as the median and range, while categorical variables were presented as number and percentages. Student's t-test was used to compare continuous variables, while χ 2 or Abbreviations: ATG = antithymocyte globulin; HCT-CI = haematopoietic cell transplantation-specific comorbidity index; MisMD = mismatched donor; MRD = matched related donor; MUD = matched unrelated donor; MMF = mycofenolate mofetil; NRM = non-relapse mortality.
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Fisher's exact test were used to analyse the frequency distribution between categorical variables. Variables with a P-value below 0.1 were entered as factors into a multivariate Cox proportional hazards regression model. A backward-stepwise selection using the Akaike information criterion (AIC) was performed to identify independent predictors for survival outcomes (iGvHD free and non-relapse survival). Hazard ratios (HRs) and 95% CIs were calculated based on the respective coefficients for these predictors. The assumption of proportional hazards was tested based on Schoenfeld residuals. 10 All statistical tests were two-tailed, and a P-value of o 0.05 was considered to be statistically significant.
RESULTS
A total of 423 patients undergoing aSCT were identified. After exclusion of patients who did not receive fluoroquinolone prophylaxis (n = 18) or whose data were incomplete (n = 6), 399 patients undergoing aSCT were eligible for further analysis. Characteristics of these patients are shown in Table 1 .
Using bivariate analysis, we identified factors associated with differences in the incidence of iGvHD (Table 2 ) and NRM (Table 3) within 100 days and 12 months after aSCT, respectively. The respective cumulative hazards for iGvHD are shown in the Supplementary Figures S1-S7 .
The results of a Cox proportional hazards analysis for the occurrence of iGvHD are shown in Table 4 . For sensitivity analysis, we performed another Cox regression analysis including the BoxCox transformed cumulative exposure of the administered antibiotic groups, for example, penicillin derivatives, carbapenems, glycopeptides, tetracycline derivatives, fluoroquinolones and clindamycin, instead of the cumulative exposure of all antibiotics and the antibiotic regimens. This analysis confirmed that penicillin (HR 1.11; 95% CI 1.01-1.35; P = 0.015) and carbapenem (HR 1.31; 95% CI 1.25-1.83; P o0.001) exposure was indeed significantly associated with an increased incidence of intestinal GvHD, while the glycopeptide exposure as well as any other antibiotic exposure was not associated with iGvHD. In order to further explore this result, we assessed whether penicillin derivatives and carbapenems were time-dependent covariates for iGvHD and the use of glycopeptides. In both case, that is, the incidence of iGvHD and the use of glycopeptides, penicillin derivatives (iGvHD: HR 1.02, 95% CI 1.01-1.03, P = 0.006; glycopeptides: HR 1.04, 95% CI 1.00-1.09, P = 0.044) and carbapenems (iGvHD: HR 1.02, 95% CI 1.01-1.04, P = 0.009; glycopeptides: HR 1.05, 95% CI 1.00-1.10, P = 0.044) were significantly associated with the studied outcome. Table 5 shows the Cox proportional hazards analysis for the NRM 1 year after transplantation. One difference between the models for these two outcomes (occurrence of iGvHD and NRM) was that age (HR 2.12, 95% CI 1.23-3.66), HCT-CI score (1-3: HR 1.68, 95% CI 0.97-2.91; 43: HR 2.10, 95% CI 1.05-4.22) and CMV status (matched: HR 0.53, 95% CI 0.33-0.85) were predictive for NRM but not for iGvHD.
For sensitivity analysis, iGVHD was excluded from the model. In this case, exposure to penicillin derivatives followed by carbapenems was again identified as an independent risk factor.
DISCUSSION
To our knowledge, this study is the first to use time-dependent covariates to establish the association and sequence of antibiotic treatment, iGvHD and poor outcome. This has the distinct advantage of allowing the conclusion that antibiotic treatment actually preceded iGvHD and was not a surrogate for patients with fatal GvHD who often develop sepsis and receive extensive antiinfective treatments during their final days. Our analysis identifies the sequence of penicillin derivatives followed by carbapenems as a risk factor for iGvHD, but not its individual components alone. Furthermore, we were able to demonstrate that this risk increases in accordance with the duration of overall exposure to antibiotics. In line with this, glycopeptides were discarded as an independent risk factor, as time-dependent covariate analysis revealed the dependence of their prescription on the previous prescription of penicillin derivatives and carbapenems. This observation is consistent with the high frequency of empirical glycopeptide add-on treatment during refractory febrile neutropenia in the aSCT setting.
Our findings thus take the next step towards establishment of a causal chain that was hypothesized based on previous data from a US American and a German cohort study performed in patients undergoing aSCT who underwent regular sampling and analysis of their faecal microbiota. The results of these studies suggest that the extent of microbiota injury, represented by a decrease in microbial diversity, correlates with iGVHD and mortality after SCT. 3, [11] [12] [13] [14] Specifically the loss of commensals from the genus Blautia in the US American cohort and from the closely related families of Lachnospiraceae and Ruminococcaceae of the class of Clostridia in the German cohort were associated with the Abbreviations: HCT-CI = haematopoietic cell transplantation-specific comorbidity index; MisMD = mismatched donor; MRD = matched related donor; MUD = matched unrelated donor. a Aplastic anaemia (n = 12), biphenotypic leukaemia (n = 1), idiopathic thrombocytopenia (n = 1), osteomyelofibrosis (n = 5) and refractory anaemia (n = 2).
Time-adjusted impact of antibiotics in aSCT patients F Farowski et al development of iGvHD. 13, 14 While the production of short-chain fatty acids with anti-inflammatory properties, namely butyrate, by these microbiota may well be critical in this process, 15 the exact underlying pathomechanisms remain to be elucidated.
A sub-analysis from the US American cohort aimed to evaluate the specific risk attributable to different antibiotic regimens used for the treatment of febrile neutropenia. In patients receiving imipenem-cilastatin or piperacillin-tazobactam as first-line treatment, the incidence of iGvHD-related mortality was significantly increased compared with patients receiving first-line aztreonam or cefepime. 3 The composition of our aSCT cohort is well comparable with this US American cohort. In both, median patient age was close to 50 years, although in our cohort, less patients received myeloablative conditioning (17% vs 36%) and mismatched grafts (23.3% vs 30%). While the work by Shono et al. 3 was exemplary in identifying those antibiotics responsible for microbiota composition changes which ultimately lead to iGVHD, we felt that statistical options for assessment of the specific relevance of timing, duration, sequence and combination of antibiotic treatment in this setting had not been fully exploited. We addressed this by adding data of high temporal granularity for timedependent covariates to the comprehensive data set of our own aSCT cohort and performed appropriate analyses to establish sequence of events.
Using this data set, we could indeed confirm the work by Shono et al. 3 in which penicillin derivatives and carbapenems were identified as risk factors for development of iGvHD. Contrasting with results from Shono et al.
3
, iGVHD but not penicillin derivatives and carbapenems were identified as risk factors for NRM. Only if, in the context of sensitivity analyses, iGVHD was removed from the model, were these antibiotics again turned into relevant risk factors. We hypothesize that this constellation confirms the notion that disruption of the gut microbiota induces iGVHD, which then contributes to increased NRM.
Complementary to the analysis by Shono et al.
, the inclusion of temporal aspects into our analysis revealed that specifically the sequential use of penicillin derivatives and carbapenems and the overall duration of their prescription should be considered problematic. From a clinical point of view, this information is of high relevance. As bloodstream infections remain a major cause of non-relapse mortality in patients undergoing aSCT, 16 empirical use of broad-spectrum antimicrobials continues as a cornerstone of supportive care in haematology. Common empirical strategies in the aSCT unit often include (i) continuation of antibiotic treatment until engraftment, even after defervescence and clinical improvement 17 and (ii) switch to a different class of broadspectrum antibiotics with the aim of a so-called escalation of antibiotic coverage in case of persistent febrile neutropenia. 18 Considering the growing evidence on severe detrimental effects by extensive antibiotic use in the early post-transplantation period and the strong evidence of futility of empirical so-called 'escalation' strategies for persistently febrile patients, [19] [20] [21] [22] there is urgent need for discussion of current treatment paradigms. Antimicrobial stewardship intervention tailored to haematological patient groups is warranted and may help reducing morbidity and Abbreviations: HCT-CI = haematopoietic cell transplantation-specific comorbidity index; MisMD = mismatched donor; MRD = matched related donor; MUD = matched unrelated donor; NRM = non-relapse mortality. a Aplastic anaemia (n = 12), biphenotypic leukaemia (n = 1), idiopathic thrombocytopenia (n = 1), osteomyelofibrosis (n = 5) and refractory anaemia (n = 2).
Time-adjusted impact of antibiotics in aSCT patientsmortality of aSCT patients by disrupting the vicious cycle of infection, antibiotics, iGvHD and immunosuppression. 23 There are certain shortcomings to our analysis that merit discussion. Most importantly, an observational study does not allow conclusions on causality, but at best may point to clinical aspects that may require further in-depth research efforts. Keeping this in mind, we made a significant effort to eliminate the effects of statistical confounders inherent to this kind of setting; however, the study would have profited from a larger sample size. This would have allowed more frequent capture of those events that occur at an advanced stage of aSCT; for example, treatment with penicillin derivatives followed by carbapenems was documented in only 25 patients.
Furthermore, data granularity could have been improved by addition of a microbiome analysis from faecal samples and immunological assessments.
Particularly the potential effect of infection as a trigger of immune activation and subsequently iGvHD remains an aspect that deserves further analyses. Indirectly, this question may be answered by the results of an ongoing randomized controlled trial assessing autologous faecal microbiota transplantation for prophylaxis of Clostridium difficile infection in SCT patients. iGVHD will be assessed as a secondary end point (NCT02269150).
In conclusion, our analysis for the first time established the sequence of events from microbiota disruption, specifically by penicillin derivatives and carbapenems, over development of iGVHD to subsequent increases in NMR. It complements previous findings by showing that patients exposed to sequential use of penicillin derivatives and carbapenems or to prolonged treatment courses are at a particularly high risk of developing iGVHD. To further validate these findings, a faecal sampling strategy has been set up in our established aSCT cohort. Proof of principle studies showing reduced iGvHD by interventions aiming at preservation of microbiota in the post-transplantation period are warranted.
